Oday Alsheikh, MD
Ophthalmology · San Antonio, TXNPI 1508070525
Payments from drug & device makers
Across 216 payments — averaging $91.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Bausch & Lomb Americas Inc.$2K
- Johnson & Johnson Surgical Vision, Inc.$785
- Glaukos Corporation$488
- Sun Pharmaceutical Industries Inc.$417
- Alcon$374
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$260%
- Food & beverage$6,725100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $14,330 |
| Bausch & Lomb Americas Inc. | 31 | $1,608 |
| Johnson & Johnson Surgical Vision, Inc. | 22 | $785 |
| Glaukos Corporation | 6 | $488 |
| Sun Pharmaceutical Industries Inc. | 18 | $417 |
| Alcon | 13 | $374 |
| Mallinckrodt Hospital Products Inc. | 17 | $313 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $206 |
| Oyster Point Pharma, Inc. | 10 | $195 |
| Regeneron | 1 | $150 |
| Thea Pharma Inc. | 7 | $131 |
| Rxsight Inc | 3 | $127 |
| Tarsus Pharmaceuticals, Inc. | 4 | $111 |
| Eyevance Pharmaceuticals LLC | 4 | $73 |
| Carl Zeiss Meditec USA, Inc. | 1 | $69 |
| Lensar, Inc. | 1 | $68 |
| Akorn Operating Company LLC | 3 | $60 |
| Novartis | 3 | $43 |
| Akorn, Inc. | 2 | $43 |
| Ocular Therapeutix, Inc. | 2 | $43 |
| Harrow Eye, LLC | 2 | $42 |
| Astellas Pharma US Inc | 2 | $40 |
| Dompe US, Inc. | 2 | $32 |
| Dutch Ophthalmic, USA | 1 | $20 |
| Sight Sciences, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
| Tearlab Corp | 1 | $14 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$410
- STELLARIS$405
- enVista MX60 IOL$283
- iDose$238
- EYLEA HD$150
- DURYSTA$149
- AcrySof IQ VIVITY$113
- iAccess Precision Blade$100
- iStent Infinite$100
- iDoseTR$100
How this compares
$19,848 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 247 | $260,016 |
| Cyclosporine | 156 | $101,563 |
| XiidraLifitegrast | 85 | $94,571 |
| ProlensaBromfenac Sodium | 201 | $71,013 |
| Bromfenac Sodium | 275 | $42,741 |
| Fluorometholone | 543 | $42,581 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 250 | $41,355 |
| Alphagan PBrimonidine Tartrate | 116 | $35,898 |
| Prednisolone Acetate | 905 | $35,495 |
| IyuzehLatanoprost/Pf | 76 | $34,418 |
| TafluprostTafluprost/Pf | 203 | $32,976 |
| LumiganBimatoprost | 49 | $27,839 |
| Brimonidine Tartrate | 186 | $27,406 |
| RhopressaNetarsudil Mesylate | 46 | $22,986 |
| ZioptanTafluprost/Pf | 57 | $22,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Lumigan, Combigan | $14,330 | $331,920433 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $1,608 | $126,443117 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm | $206 | $90,473299 claims |
| Thea Pharma Inc.Iyuzeh | $131 | $34,41876 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $15 | $28,17257 claims |
| Akorn, Inc.Zioptan | $43 | $22,01057 claims |
| AlconSimbrinza | $374 | $11,52131 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $13 | $7,47115 claims |
| NovartisIlevro | $43 | $6,00415 claims |
| Eyevance Pharmaceuticals LLCFlarex | $73 | $5,32843 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in San Antonio
- Michael SingerSan Antonio$4.2M
- Gregory ParkhurstSan Antonio$4.1M
- Calvin MeinSan Antonio$1.3M
- James LehmannSan Antonio$1.1M
- Darren BellSan Antonio$906K
- Gregory BruninSan Antonio$709K
- Richard EvansSan Antonio$656K
- Edward RashidSan Antonio$523K
- Kenneth MaverickSan Antonio$485K
- Kundandeep NagiSan Antonio$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.